Skip to main content

Table 5 Adjusted odds ratios for FN in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively (Narrow Definition of FN)

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

  Adjusted Odds Ratio for FN (95% CI, p-value)*
Cycle 1 Cycle 2 Cycles ≥3 Last Cycle All Cycles
Commercial
 Independent Variables
  No PEG Prophylaxis 4.2 (3.8–4.7, < 0.001) 4.1 (3.3–4.9, < 0.001) 3.3 (2.9–3.8, < 0.001) 3.2 (2.7–3.8, < 0.001) 4.2 (3.9–4.5, < 0.001)
  FN in Prior Cycle 5.1 (3.7–7.0, < 0.001) 5.9 (4.9–7.0, < 0.001) 3.9 (3.0–5.0, < 0.001) 3.1 (2.6–3.5, < 0.001)
  Regimen
   TAC 4.4 (3.8–5.1, < 0.001) 2.2 (1.6–3.2, < 0.001) 3.0 (2.4–3.8, < 0.001) 2.7 (2.0–3.6, < 0.001) 4.1 (3.3–5.2, < 0.001)
   TC
   TCH 1.0 (0.9–1.1, 0.963) 1.4 (1.1–1.8, 0.009) 1.2 (1.0–1.4, 0.130) 1.2 (0.9–1.5, 0.191) 1.3 (1.0–1.6, 0.040)
   CHOP±R 1.4 (1.2–1.6, < 0.001) 2.0 (1.5–2.7, < 0.001) 3.5 (2.9–4.4, < 0.001) 1.7 (1.4–2.1, < 0.001) 3.0 (2.0–4.5, < 0.001)
  Age
   18–49
   50–64 1.1 (1.0–1.2, 0.216) 1.1 (0.9–1.4, 0.332) 1.0 (0.9–1.2, 0.671) 1.3 (1.1–1.6, 0.010) 1.1 (1.0–1.2, 0.207)
   65–74 1.5 (1.3–1.8, < 0.001) 1.2 (0.8–1.6, 0.354) 1.4 (1.1–1.8, 0.002) 1.6 (1.2–2.1, 0.003) 1.4 (1.3–1.6, < 0.001)
   ≥ 75 2.1 (1.7–2.7, < 0.001) 1.7 (1.1–2.6, 0.012) 2.0 (1.5–2.6, < 0.001) 4.0 (2.9–5.5, < 0.001) 2.1 (1.7–2.4, < 0.001)
Medicare
 Independent Variables
  No PEG Prophylaxis 2.0 (1.9–2.2, < 0.001) 2.2 (2.0–2.5, < 0.001) 1.6 (1.5–1.8, < 0.001) 1.3 (1.2–1.4, < 0.001) 1.9 (1.8–2.0, < 0.001)
  FN in Prior Cycle 4.6 (4.0–5.3, < 0.001) 4.1 (3.8–4.4, < 0.001) 2.4 (2.1–2.6, < 0.001) 2.7 (2.5–2.9, < 0.001)
  Regimen
   TAC 3.1 (2.7–3.7, < 0.001) 2.5 (1.9–3.5, < 0.001) 2.8 (2.3–3.5, < 0.001) 2.5 (2.0–3.1, < 0.001) 2.7 (2.4–3.0, < 0.001)
   TC
   TCH 0.6 (0.6–0.7, < 0.001) 0.7 (0.5–0.9, 0.001) 0.6 (0.5–0.8, < 0.001) 0.7 (0.6–0.8, < 0.001) 0.6 (0.5–0.6, < 0.001)
  CHOP±R 1.6 (1.5–1.7, < 0.001) 2.1 (1.9–2.5, < 0.001) 2.9 (2.6–3.2, < 0.001) 2.1 (1.9–2.3, < 0.001) 1.9 (1.8–2.0, < 0.001)
  Age
  65–74
   75–84 1.2 (1.1–1.3, < 0.001) 1.0 (0.8–1.1, 0.759) 1.1 (1.0–1.2, 0.011) 1.2 (1.1–1.4, < 0.001) 1.1 (1.1–1.2, < 0.001)
   ≥ 85 1.4 (1.3–1.6, < 0.001) 1.1 (1.0–1.3, 0.047) 1.2 (1.1–1.4, < 0.001) 1.6 (1.5–1.8, < 0.001) 1.3 (1.3–1.4, < 0.001)
  1. FN febrile neutropenia, PEG pegfilgrastim, TC docetaxel + cyclophosphamide, TAC docetaxel + doxorubicin + cyclophosphamide, TCH docetaxel + cyclophosphamide + trastuzumab, CHOP cyclophosphamide + doxorubicin + vincristine + prednisone, R rituximab
  2. *Adjusted for other characteristics of patients listed in Table 1; additional covariates selected via backward selection method